(A031203) Randomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) with Commercially Supplied Sunitinib in Patients with Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma
Description: 

To determine if patients with renal cancer treated with cabozantinib will have improved progression-free survival compared to patients treated with sunitinib.

Study Number: 

NCG 242013

Phase: 
II
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01835158

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.